Louisville, KENTUCKY14 Active Studies

Interstitial Cystitis Clinical Trials in Louisville, KENTUCKY

Find 14 actively recruiting interstitial cystitis clinical trials in Louisville, KENTUCKY. Connect with local research sites and explore new treatment options.

14
Active Trials
12
Sponsors
3,291
Enrolling

Recruiting Interstitial Cystitis Studies in Louisville

RecruitingLouisville, KENTUCKYNCT03401398

Stress Hydrocortisone In Pediatric Septic Shock

SHIPSS is a multi-institutional, prospective, controlled, randomized, double-blinded interventional trial that will examine the potential benefits and risks of adjunctive hydrocortisone prescribed for...

500 participants
Jerry Zimmerman
View Study Details
RecruitingLouisville, KENTUCKYNCT04728893

Efficacy and Safety of Nemtabrutinib (MK-1026) in Participants With Hematologic Malignancies (MK-1026-003)

The purpose of this study is to evaluate the safety and efficacy of nemtabrutinib (formerly ARQ 531) in participants with hematologic malignancies of chronic lymphocytic leukemia (CLL)/ small lymphocy...

490 participants
Merck Sharp & Dohme LLC
View Study Details
RecruitingLouisville, KENTUCKYNCT07076121

A Study Comparing BMS-986504 in Combination With Nab-paclitaxel and Gemcitabine Versus Placebo in Combination With Nab-paclitaxel and Gemcitabine in Participants With Untreated Metastatic Pancreatic Ductal Adenocarcinoma With Homozygous MTAP Deletion (MountainTAP-30)

The purpose of this study is to assess the safety and efficacy of BMS-986504, a selective, MTA-cooperative PRMT5 inhibitor, in combination with Nab-paclitaxel/Gemcitabine (nab-p/gem) versus placebo in...

470 participants
Bristol-Myers Squibb
View Study Details
RecruitingLouisville, KENTUCKYNCT05156983

A Study of TAK-330 to Reverse the Effects of Factor Xa Inhibitors For Adults Needing Urgent Surgery

The aim of this study is to find out the effects of TAK-330 compared with four-factor prothrombin complex concentrate (4F-PCC) as part of standard treatment other than Prothromplex Total for anticoagu...

328 participants
Takeda
View Study Details
RecruitingLouisville, KENTUCKYNCT06439082

A Study to Investigate the Efficacy and Safety of Crizanlizumab (5 mg/kg) Compared With Placebo in Adolescent and Adult Sickle Cell Disease Patients Who Experience Frequent Vaso-Occlusive Crises (SPARKLE)

A phase III, multi-center, randomized, placebo-controlled, double-blind study to assess efficacy and safety of crizanlizumab (5 mg/kg) versus placebo, with or without hydroxyurea/hydroxycarbamide ther...

315 participants
Novartis Pharmaceuticals
View Study Details
RecruitingLouisville, KENTUCKYNCT05263206

Efficacy and Safety of Subcutaneous Dupilumab for the Treatment of Adult Participants With Chronic Pruritus of Unknown Origin (CPUO) (LIBERTY-CPUO-CHIC)

The main objective of the study is to assess efficacy and safety of dupilumab given up to 24 weeks in adults with CPUO. This is a master protocol which includes 2 parallel-treatment, double-blind, 2-...

284 participants
Sanofi
View Study Details
RecruitingLouisville, KENTUCKYNCT05482893

Spevatamig (PT886) as Monotherapy or in Combination With Chemo and/or ICI, for the Treatment of Patients With Advanced Gastric, Gastroesophageal Junction, Pancreatic Ductal or Biliary Tract Carcinomas (the TWINPEAK Study)

This is a first-in-human, Phase 1/2, open-label, dose escalation and dose expansion and combination study designed to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and prelimi...

258 participants
Phanes Therapeutics
View Study Details
RecruitingLouisville, KENTUCKYNCT06947993

Platform Study to Evaluate the Efficacy and Safety of Investigational Compound(s) in Patients With Moderate to Severe Atopic Dermatitis

This trial is designed to evaluate multiple compounds in participants with moderate to severe atopic dermatitis (AD)....

224 participants
Novartis Pharmaceuticals
View Study Details
RecruitingLouisville, KENTUCKYNCT05571059

Oral Ifetroban in Patients With Idiopathic Pulmonary Fibrosis (IPF)

Ifetroban prevents and treats lung fibrosis due to multiple causes (bleomycin, genetic, radiation). The safety and efficacy of oral ifetroban will be assessed in patients with IPF....

128 participants
Cumberland Pharmaceuticals
View Study Details
RecruitingLouisville, KENTUCKYNCT06850805

Efficacy and Safety of 186 mcg of OPN-375 Nasal Spray Twice a Day (BID) in Adolescents With Chronic Rhinosinusitis Without Nasal Polyps

This is a 12-Week randomized, double-blind, placebo-controlled, parallel-group, multicenter study evaluating the efficacy and safety of intranasal administration of 186 µg of OPN-375 twice a day (BID)...

84 participants
Optinose US Inc.
View Study Details
RecruitingLouisville, KENTUCKYNCT05249101

A Study of Ivaltinostat Plus Capecitabine or Capecitabine in Metastatic Pancreatic Adenocarcinoma

This study is a Phase 1b/2, dose-escalation, randomized, multicenter study to assess the efficacy, safety, tolerability, and PK of ivaltinostat in combination with capecitabine and capecitabine monoth...

70 participants
CG Pharmaceuticals, Inc
View Study Details
RecruitingLouisville, KENTUCKYNCT06145035

Single or Repeated Intravenous Administration of umbiliCAl Cord Mesenchymal sTrOmal Cells in Ischemic Cardiomyopathy

This is a Phase IIA, randomized, double blind, placebo controlled, multicenter study designed to assess the safety, feasibility, and efficacy of umbilical cord derived mesenchymal stromal cells (UC MS...

60 participants
Roberto Bolli
View Study Details
RecruitingLouisville, KENTUCKYNCT04640142

Study to Evaluate the Pharmacokinetics, Efficacy, Tolerability, and Safety of Subcutaneous Human Immunoglobulin (Newnorm) in Patients With Primary Immunodeficiency Diseases

Prospective, open-label, single-arm, multicentre Phase 3 study to evaluate the pharmacokinetics, efficacy, tolerability, and safety of subcutaneous human immunoglobulin (Newnorm) in patients with prim...

50 participants
Octapharma
View Study Details
RecruitingLouisville, KENTUCKYNCT04929236

Study to Evaluate Safety and Efficacy of Different PANZYGA Dose Regimens in Pediatric Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) Patients

Safety and Efficacy of Different PANZYGA Dose Regimens in Pediatric Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) Patients...

30 participants
Octapharma
View Study Details

About Interstitial Cystitis Clinical Trials in Louisville

Interstitial cystitis/bladder pain syndrome is a chronic condition causing bladder pressure, bladder pain, and sometimes pelvic pain. It primarily affects women and can significantly impact quality of life. Treatment includes dietary changes, bladder instillations, oral medications, and neuromodulation.

There are currently 14 interstitial cystitis clinical trials recruiting participants in Louisville, KENTUCKY. These studies are seeking a combined 3,291 participants. Research is being sponsored by Jerry Zimmerman, Merck Sharp & Dohme LLC, Bristol-Myers Squibb and 9 other organizations. Clinical trial participation is free and participants receive study-related medical care at no cost.

Interstitial Cystitis Clinical Trials in Louisville — FAQ

Are there interstitial cystitis clinical trials in Louisville?

Yes, there are 14 interstitial cystitis clinical trials currently recruiting in Louisville, KENTUCKY. Browse the studies on this page to find one that fits.

How do I join a clinical trial in Louisville?

Browse the studies listed above, click one that interests you, and complete the free eligibility form. A study coordinator at the Louisville research site will contact you about next steps.

Are clinical trials in Louisville free?

Yes, clinical trial participation is always free. Study-related treatment, medical tests, and doctor visits are provided at no cost. Many Louisville studies also compensate for your time and travel.

What interstitial cystitis treatments are being tested?

The 14 active trials in Louisville are testing new therapies including novel drugs, biologics, and treatment approaches for interstitial cystitis.

Data updated March 2, 2026 from ClinicalTrials.gov